company background image
XENT

Intersect ENTNasdaqGM:XENT Stock Report

Last Price

US$27.13

Market Cap

US$907.8m

7D

-0.4%

1Y

2.0%

Updated

21 Jan, 2022

Data

Company Financials +
XENT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health3/6
Dividends0/6

XENT Stock Overview

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States.

Intersect ENT Competitors

Medtronic

NYSE:MDT

US$142.0b

Stryker

NYSE:SYK

US$96.1b

Johnson & Johnson

NYSE:JNJ

US$434.0b

Olympus

TSE:7733

JP¥3.2t

Price History & Performance

Summary of all time highs, changes and price drops for Intersect ENT
Historical stock prices
Current Share PriceUS$27.13
52 Week HighUS$28.17
52 Week LowUS$15.92
Beta1.56
1 Month Change0.074%
3 Month Change0.70%
1 Year Change1.99%
3 Year Change-6.45%
5 Year Change104.76%
Change since IPO109.99%

Recent News & Updates

Aug 02
A Look At The Fair Value Of Intersect ENT, Inc. (NASDAQ:XENT)

A Look At The Fair Value Of Intersect ENT, Inc. (NASDAQ:XENT)

Today we will run through one way of estimating the intrinsic value of Intersect ENT, Inc. ( NASDAQ:XENT ) by taking...

Shareholder Returns

XENTUS Medical EquipmentUS Market
7D-0.4%-4.5%-6.1%
1Y2.0%-1.4%4.2%

Return vs Industry: XENT exceeded the US Medical Equipment industry which returned -0.9% over the past year.

Return vs Market: XENT underperformed the US Market which returned 6.6% over the past year.

Price Volatility

Is XENT's price volatile compared to industry and market?
XENT volatility
XENT Average Weekly Movement0.6%
Medical Equipment Industry Average Movement8.2%
Market Average Movement6.7%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.4%

Stable Share Price: XENT is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 1% a week.

Volatility Over Time: XENT's weekly volatility (1%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003406Tom Westhttps://www.intersectent.com

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL and PROPEL Mini, which are steroid releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries.

Intersect ENT Fundamentals Summary

How do Intersect ENT's earnings and revenue compare to its market cap?
XENT fundamental statistics
Market CapUS$907.81m
Earnings (TTM)-US$88.68m
Revenue (TTM)US$104.31m

8.7x

P/S Ratio

-10.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
XENT income statement (TTM)
RevenueUS$104.31m
Cost of RevenueUS$25.57m
Gross ProfitUS$78.74m
ExpensesUS$167.42m
Earnings-US$88.68m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.65
Gross Margin75.49%
Net Profit Margin-85.02%
Debt/Equity Ratio688.7%

How did XENT perform over the long term?

See historical performance and comparison

Valuation

Is Intersect ENT undervalued compared to its fair value and its price relative to the market?

55.99x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate XENT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate XENT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: XENT is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: XENT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XENT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XENT is overvalued based on its PB Ratio (56x) compared to the US Medical Equipment industry average (3.4x).


Future Growth

How is Intersect ENT forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

24.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XENT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XENT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XENT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XENT's revenue (18% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: XENT's revenue (18% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: XENT is forecast to be unprofitable in 3 years.


Past Performance

How has Intersect ENT performed over the past 5 years?

-33.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XENT is currently unprofitable.

Growing Profit Margin: XENT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XENT is unprofitable, and losses have increased over the past 5 years at a rate of 33.3% per year.

Accelerating Growth: Unable to compare XENT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XENT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (51.2%).


Return on Equity

High ROE: XENT has a negative Return on Equity (-546.92%), as it is currently unprofitable.


Financial Health

How is Intersect ENT's financial position?


Financial Position Analysis

Short Term Liabilities: XENT's short term assets ($119.9M) exceed its short term liabilities ($50.8M).

Long Term Liabilities: XENT's short term assets ($119.9M) do not cover its long term liabilities ($161.0M).


Debt to Equity History and Analysis

Debt Level: XENT's net debt to equity ratio (189.1%) is considered high.

Reducing Debt: Insufficient data to determine if XENT's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XENT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: XENT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 18.1% each year


Dividend

What is Intersect ENT current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate XENT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XENT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XENT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XENT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XENT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Tom West (57 yo)

2.5yrs

Tenure

US$3,693,598

Compensation

Mr. Thomas A. West, also known as Tom, is a Director at Orthofix Medical Inc. since December 2021. He has been President, Chief Executive Officer and Director of Intersect ENT, Inc. since July 22, 2019. Mr...


CEO Compensation Analysis

Compensation vs Market: Tom's total compensation ($USD3.69M) is above average for companies of similar size in the US market ($USD2.38M).

Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: XENT's management team is considered experienced (2.2 years average tenure).


Board Members

Experienced Board: XENT's board of directors are considered experienced (4.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.


Top Shareholders

Company Information

Intersect ENT, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Intersect ENT, Inc.
  • Ticker: XENT
  • Exchange: NasdaqGM
  • Founded: 2003
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$907.815m
  • Shares outstanding: 33.46m
  • Website: https://www.intersectent.com

Number of Employees


Location

  • Intersect ENT, Inc.
  • 1555 Adams Drive
  • Menlo Park
  • California
  • 94025
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/21 23:50
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.